risankizumab vs SHR-1139
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT02684370 · Phase 3 · completed
This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.
Next expected readout: April 2028 · NCT04862286 (registry estimate)
Reported efficacy
Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 (Baseline, Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16; Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 (met)
Result source: NCT02672852
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
NCT07051538 · Phase 1 · completed
This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07719530 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | risankizumab | SHR-1139 |
|---|---|---|
| PASI 75 | 85.2% vs 85.7%vs UstekinumabNCT0443560019 other results
| —Not reported |
| PASI 90 | 75.3% vs 4.9%+70.4 vs placeboNCT0268437022 other results
| —Not reported |
| PASI 100 | 35.9% vs 0%+35.9 vs placeboNCT0268437020 other results
| —Not reported |
| sPGA 0/1 | 87.8% vs 7.8%+80 vs placeboNCT0268437028 other results
| —Not reported |
| DLQI, change | -17 vs -9.7vs FumadermNCT03255382 | —Not reported |
PASI 75
- risankizumab
- 85.2% vs 85.7%vs UstekinumabNCT04435600
19 other results
- 83.3% vs 85.7% NCT04435600
- 92.3% vs 85.7% NCT04435600
- 86.7% vs 85.7% NCT04435600
- 88.7% vs 8% NCT02672852
- 90.8% vs 6.1% NCT02684357
- 90.7% vs 71.7% NCT02694523
- 86.8% vs 70% NCT02684370
- 88.8% vs 69.7% NCT02684357
- 93.3% vs 26.7% NCT03255382
- 86.7% vs 20% NCT03255382
- 75% vs 8.3% NCT03255382
- 13.3% vs 3.3% NCT03255382
- 94.5% vs 8.6% NCT03000075
- 89.7% vs 8.6% NCT03000075
- 90.5% vs 77.5% NCT02054481
- 97.6% vs 77.5% NCT02054481
- 67.4% vs 77.5% NCT02054481
- 84.7% vs 18.8% NCT04908475
- 94% vs 77.5% NCT02054481
- SHR-1139
- —Not reported
PASI 90
- risankizumab
- 75.3% vs 4.9%+70.4 vs placeboNCT02684370
22 other results
- 73.2% vs 2% NCT02672852
- 74.8% vs 2% NCT02684357
- 62.9% vs 3.8% NCT03875482
- 72.4% vs 47.4% NCT02694523
- 73.8% vs 65.6% NCT03478787
- 75.3% vs 42% NCT02684370
- 74.8% vs 47.5% NCT02684357
- 64.8% vs 60.7% NCT04435600
- 76.7% vs 11.7% NCT03255382
- 61.7% vs 5% NCT03255382
- 38.3% vs 1.7% NCT03255382
- 1.7% vs 0% NCT03255382
- 83.3% vs 60.7% NCT04435600
- 84.6% vs 60.7% NCT04435600
- 76.7% vs 60.7% NCT04435600
- 74.5% vs 1.7% NCT03000075
- 75.9% vs 1.7% NCT03000075
- 81% vs 40% NCT02054481
- 73.2% vs 40% NCT02054481
- 32.6% vs 40% NCT02054481
- 55.9% vs 5.1% NCT04908475
- 77.1% vs 40% NCT02054481
- SHR-1139
- —Not reported
PASI 100
- risankizumab
- 35.9% vs 0%+35.9 vs placeboNCT02684370
20 other results
- 47.2% vs 1% NCT02672852
- 50.7% vs 2% NCT02684357
- 38.1% vs 1.9% NCT03875482
- 35.9% vs 12% NCT02684370
- 50.7% vs 24.2% NCT02684357
- 39.9% vs 23% NCT02694523
- 40.7% vs 17.9% NCT04435600
- 35% vs 1.7% NCT03255382
- 23.3% vs 1.7% NCT03255382
- 5% vs 1.7% NCT03255382
- 0% vs 0% NCT03255382
- 41.7% vs 17.9% NCT04435600
- 53.8% vs 17.9% NCT04435600
- 43.3% vs 17.9% NCT04435600
- 32.7% vs 0% NCT03000075
- 22.4% vs 0% NCT03000075
- 50% vs 17.5% NCT02054481
- 41.5% vs 17.5% NCT02054481
- 14% vs 17.5% NCT02054481
- 45.8% vs 17.5% NCT02054481
- SHR-1139
- —Not reported
sPGA 0/1
- risankizumab
- 87.8% vs 7.8%+80 vs placeboNCT02684370
28 other results
- 83.5% vs 7% NCT02672852
- 83.7% vs 5.1% NCT02684357
- 78.1% vs 9.6% NCT03875482
- 83.7% vs 60.2% NCT02694523
- 79.6% vs 75% NCT04435600
- 68.5% vs 67.9% NCT04435600
- 83.3% vs 75% NCT04435600
- 84.6% vs 75% NCT04435600
- 90% vs 75% NCT04435600
- 83.3% vs 67.9% NCT04435600
- 84.6% vs 67.9% NCT04435600
- 83.3% vs 67.9% NCT04435600
- 32.2% vs 11.5% NCT04713592
- 87.8% vs 63% NCT02684370
- 83.7% vs 61.6% NCT02684357
- 82.2% vs 65% NCT02684370
- 82.3% vs 64.6% NCT02684357
- 91.7% vs 31.7% NCT03255382
- 90% vs 33.3% NCT03255382
- 81.7% vs 15% NCT03255382
- 33.3% vs 3.3% NCT03255382
- 75.4% vs 18.4% NCT04908475
- 92.7% vs 10.3% NCT03000075
- 86.2% vs 10.3% NCT03000075
- 90.5% vs 67.5% NCT02054481
- 90.2% vs 67.5% NCT02054481
- 62.8% vs 67.5% NCT02054481
- 90.4% vs 67.5% NCT02054481
- SHR-1139
- —Not reported
DLQI, change
- risankizumab
- -17 vs -9.7vs FumadermNCT03255382
- SHR-1139
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SHR-1139: no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. risankizumab: 4 of 4 rows · SHR-1139: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | risankizumab |
|---|---|
| Dropout rate | 1.6%Risankizumab (Part A)a NCT02684370 · Phase 3 show 53 more results—Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 1%Risankizumab (Part A1) NCT02672852 · Phase 3 —Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 0%Part 1: Risankizumab NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 —Part 2 Period A: Risankizumab NCT04435600 · Phase 3 —Part 2 Period C: Risankizumab NCT04435600 · Phase 3 —Part 3: Risankizumab NCT04435600 · Phase 3 —Part 4: Risankizumab NCT04435600 · Phase 3 0.7%Risankizumab (Part A) NCT02684357 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 —Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 —Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 2.3%Risankizumab (Part A) NCT02694523 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 1.8%Study-G Risankizumab (Period A) NCT05969223 · Phase 4 —Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 0%Study-S Risankizumab (Period A) NCT05969223 · Phase 4 —Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 —Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 26.2%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence 3.4%Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 16% NCT04102007 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 11.1% NCT03875508 · Phase 3 · registry result, not featured evidence 12.4% NCT03875482 · Phase 3 · registry result, not featured evidence 7.9% NCT03478787 · Phase 3 · registry result, not featured evidence 0% NCT03255382 · Phase 3 · registry result, not featured evidence 70%600 mg NCT05283135 · Phase 2 · registry result, not featured evidence 70%300 mg NCT05283135 · Phase 2 · registry result, not featured evidence —180 mg NCT02203851 · Phase 2 · registry result, not featured evidence —90 mg NCT02203851 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 4.8%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 4.9%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 9.3%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.3%Risankizumab (Part A)a NCT02684370 · Phase 3 show 53 more results—Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 0.2%Risankizumab (Part A1) NCT02672852 · Phase 3 —Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 —Part 1: Risankizumab NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 —Part 2 Period A: Risankizumab NCT04435600 · Phase 3 —Part 2 Period C: Risankizumab NCT04435600 · Phase 3 —Part 3: Risankizumab NCT04435600 · Phase 3 —Part 4: Risankizumab NCT04435600 · Phase 3 0%Risankizumab (Part A) NCT02684357 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 —Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 —Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 1%Risankizumab (Part A) NCT02694523 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 —Study-G Risankizumab (Period A) NCT05969223 · Phase 4 —Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 —Study-S Risankizumab (Period A) NCT05969223 · Phase 4 —Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 —Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 6.5%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence 1.1%Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 1.6% NCT04102007 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 0.9% NCT03875508 · Phase 3 · registry result, not featured evidence 0% NCT03875482 · Phase 3 · registry result, not featured evidence 0.6% NCT03478787 · Phase 3 · registry result, not featured evidence 0% NCT03255382 · Phase 3 · registry result, not featured evidence —600 mg NCT05283135 · Phase 2 · registry result, not featured evidence —300 mg NCT05283135 · Phase 2 · registry result, not featured evidence —180 mg NCT02203851 · Phase 2 · registry result, not featured evidence —90 mg NCT02203851 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 2.4%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 2.3%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 2.3%Risankizumab (Part A)a NCT02684370 · Phase 3 show 53 more results5.4%Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 2%Risankizumab (Part A1) NCT02672852 · Phase 3 11.7%Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 0%Part 1: Risankizumab NCT04435600 · Phase 3 10%Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 0%Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 0%Part 2 Period A: Risankizumab NCT04435600 · Phase 3 0%Part 2 Period C: Risankizumab NCT04435600 · Phase 3 0%Part 3: Risankizumab NCT04435600 · Phase 3 0%Part 4: Risankizumab NCT04435600 · Phase 3 2%Risankizumab (Part A) NCT02684357 · Phase 3 4.5%Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 5.7%Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 10.5%Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 3.3%Risankizumab (Part A) NCT02694523 · Phase 3 4.1%Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 1.8%Study-G Risankizumab (Period A) NCT05969223 · Phase 4 1.9%Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 5.9%Study-S Risankizumab (Period A) NCT05969223 · Phase 4 5.9%Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 0.8%Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence 0%Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 2.9%Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence 6.9%Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 20%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence —Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence 5.7%Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence 6%Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 7% NCT04102007 · Phase 3 · registry result, not featured evidence 25%150 mg NCT03022045 · Phase 3 · registry result, not featured evidence 50%150 mg NCT03022045 · Phase 3 · registry result, not featured evidence 20%75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 0%75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 5.6% NCT03875508 · Phase 3 · registry result, not featured evidence 1% NCT03875482 · Phase 3 · registry result, not featured evidence 5.5% NCT03478787 · Phase 3 · registry result, not featured evidence 1.7% NCT03255382 · Phase 3 · registry result, not featured evidence 0%600 mg NCT05283135 · Phase 2 · registry result, not featured evidence 10%300 mg NCT05283135 · Phase 2 · registry result, not featured evidence 8.7%180 mg NCT02203851 · Phase 2 · registry result, not featured evidence 13.8%90 mg NCT02203851 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 3.6%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 1.9%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 7.4%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 3.4%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 1.8%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 14.6%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 11.6%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a viral upper respiratory tract infection 6.6% (placebo 5.9%) upper respiratory tract infection 5.6% (placebo 2%) headache 3% (placebo 2%) NCT02684370 · Phase 3 show 48 more resultsviral upper respiratory tract infection 13.5% (placebo 5.9%) upper respiratory tract infection 10.1% (placebo 2%) headache 1.7% (placebo 2%) NCT02684370 · Phase 3 nasopharyngitis 5.2% (placebo 6%) headache 3.4% (placebo 0%) arthralgia 1.7% (placebo 2%) NCT02672852 · Phase 3 nasopharyngitis 20.7% (placebo 6%) upper respiratory tract infection 14.4% (placebo 5%) arthralgia 9% (placebo 2%) NCT02672852 · Phase 3 headache 16.7% (placebo 4.8%) pyrexia 16.7% (placebo 0%) abdominal pain 8.3% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 40% (placebo 9.5%) covid-19 20% (placebo 9.5%) conjunctivitis 10% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 22.7% (placebo 9.5%) headache 18.2% (placebo 4.8%) skin papilloma 13.6% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 18.5% (placebo 9.5%) covid-19 9.3% (placebo 9.5%) headache 5.6% (placebo 4.8%) NCT04435600 · Phase 3 pyrexia 25% (placebo 0%) bacterial vaginosis 12.5% (placebo 0%) chills 12.5% (placebo 0%) NCT04435600 · Phase 3 cough 15.4% (placebo 4.8%) upper respiratory tract infection 15.4% (placebo 4.8%) blood potassium increased 7.7% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 31.3% (placebo 9.5%) pyrexia 12.5% (placebo 0%) cough 9.4% (placebo 4.8%) NCT04435600 · Phase 3 upper respiratory tract infection 3.7% (placebo 2%) viral upper respiratory tract infection 3.4% (placebo 2%) influenza 2% (placebo 1%) NCT02684357 · Phase 3 viral upper respiratory tract infection 11.7% (placebo 2%) upper respiratory tract infection 8.2% (placebo 2%) diarrhoea 2.1% (placebo 3.1%) NCT02684357 · Phase 3 viral upper respiratory tract infection 26.4% upper respiratory tract infection 7.5% headache 5.7% NCT02694523 · Phase 3 viral upper respiratory tract infection 23.7% hypertension 7.9% upper respiratory tract infection 7.9% NCT02694523 · Phase 3 viral upper respiratory tract infection 8.6% upper respiratory tract infection 7% headache 4% NCT02694523 · Phase 3 viral upper respiratory tract infection 13.3% upper respiratory tract infection 11.6% hypertension 3.1% NCT02694523 · Phase 3 upper respiratory tract infection 7.3% (placebo 3.7%) covid-19 3.6% (placebo 3.7%) nasopharyngitis 3.6% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 7.4% (placebo 3.7%) covid-19 3.7% (placebo 3.7%) nasopharyngitis 3.7% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 11.8% (placebo 3.7%) covid-19 7.8% (placebo 3.7%) nasopharyngitis 2% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 11.8% (placebo 3.7%) covid-19 7.8% (placebo 3.7%) nasopharyngitis 2% (placebo 3.7%) NCT05969223 · Phase 4 covid-19 11% nasopharyngitis 3.4% headache 2.5% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 12.5% nasopharyngitis 10.4% hypertension 6.3% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 11.8% nasopharyngitis 9.8% upper respiratory tract infection 5.9% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 16.4% nasopharyngitis 9.5% hypertension 5.2% NCT04908475 · Phase 4 · registry result, not featured evidence 150 mg nasopharyngitis 22.1% covid-19 16.6% upper respiratory tract infection 14.4% NCT03047395 · Phase 3 · registry result, not featured evidence covid-19 2.3% (placebo 2.3%) NCT04713592 · Phase 3 · registry result, not featured evidence covid-19 14.3% (placebo 2.3%) NCT04713592 · Phase 3 · registry result, not featured evidence 150 mg viral upper respiratory tract infection 75% otitis media 50% acne 25% NCT03022045 · Phase 3 · registry result, not featured evidence 150 mg dehydration 50% abdominal pain upper 25% acne 25% NCT03022045 · Phase 3 · registry result, not featured evidence 75 mg viral upper respiratory tract infection 60% constipation 20% diarrhoea 20% NCT03022045 · Phase 3 · registry result, not featured evidence 75 mg alanine aminotransferase increased 25% aspartate aminotransferase increased 25% erythema 25% NCT03022045 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.4% upper respiratory tract infection 5.6% NCT03875508 · Phase 3 · registry result, not featured evidence nasopharyngitis 21.3% upper respiratory tract infection 12.8% arthralgia 5.5% NCT03478787 · Phase 3 · registry result, not featured evidence nasopharyngitis 58.3% headache 8.3% oropharyngeal pain 8.3% NCT03255382 · Phase 3 · registry result, not featured evidence 600 mg upper respiratory infection 50% common cold 30% covid-19 infection 30% NCT05283135 · Phase 2 · registry result, not featured evidence 300 mg upper respiratory infection 20% bleeding internal hemorrhoids 10% bursitis, left elbow 10% NCT05283135 · Phase 2 · registry result, not featured evidence 180 mg upper respiratory tract infection 17.4% dermatitis contact 13% nasopharyngitis 13% NCT02203851 · Phase 2 · registry result, not featured evidence 90 mg nasopharyngitis 18.4% upper respiratory tract infection 12.6% arthralgia 10.3% NCT02203851 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 29.6% (placebo 13.8%) arthralgia 11.1% (placebo 1.7%) oral herpes 7.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 18.2% (placebo 13.8%) arthralgia 3.6% (placebo 1.7%) back pain 1.8% (placebo 1.7%) NCT03000075 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 20.4% (placebo 13.8%) dental caries 7.4% (placebo 1.7%) blood triglycerides increased 5.6% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg nasopharyngitis 29.6% (placebo 13.8%) arthralgia 11.1% (placebo 1.7%) asteatosis 7.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg diabetes mellitus 5.2% (placebo 1.7%) nasopharyngitis 5.2% (placebo 13.8%) back pain 3.4% (placebo 1.7%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg nasopharyngitis 21.4% (placebo 13.8%) hepatic function abnormal 5.4% (placebo 0%) influenza 5.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 180 mg nasopharyngitis 26.2% arthralgia 7.1% headache 7.1% NCT02054481 · Phase 2 · registry result, not featured evidence 90 mg nasopharyngitis 34.1% back pain 9.8% gastroenteritis 9.8% NCT02054481 · Phase 2 · registry result, not featured evidence 18 mg nasopharyngitis 34.9% headache 11.6% folliculitis 7% NCT02054481 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
risankizumab
show 34 more results
show 36 more results
show 15 more results
show 27 more results
show 7 more results
show 29 more results
show 3 more results
show 12 more results
show 13 more results
show 4 more results
show 13 more results
show 15 more results
+ 47 further endpoints in the CSV export.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03398148 · Phase 2/3 · completed
Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.
Next expected readout: August 2027 · NCT06880744 (registry estimate)
Reported efficacy
clinical remission + endoscopic improvement met (met)
Result source: INSPIRE/COMMAND
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07232576 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | risankizumab | SHR-1139 |
|---|---|---|
| Clinical remission (induction) | 20.3% vs 6.2%+14.1 vs placeboNCT033981484 other results
| —Not reported |
| Clinical remission (maintenance) | —Trial running · NCT03398135 | —Not reported |
| Clinical response (induction) | 64.3% vs 35.7%+28.6 vs placeboNCT033981489 other results
| —Not reported |
| Endoscopic improvement (induction) | 36.5% vs 12.1%+24.4 vs placeboNCT03398148 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT03398135 | —Not reported |
Clinical remission (induction)
- risankizumab
- 20.3% vs 6.2%+14.1 vs placeboNCT03398148
4 other results
- 12.4% vs 1.7% NCT03398148
- 9.8% vs 1.7% NCT03398148
- 10.3% vs 1.7% NCT03398148
- 11.5% vs 1.7% NCT03398148
- SHR-1139
- —Not reported
Clinical remission (maintenance)
- risankizumab
- —Trial running · NCT03398135
- SHR-1139
- —Not reported
Clinical response (induction)
- risankizumab
- 64.3% vs 35.7%+28.6 vs placeboNCT03398148
9 other results
- 52.2% vs 30.5% NCT03398148
- 46.2% vs 20% NCT03398148
- 43.5% vs 25% NCT03398148
- 45.9% vs 20% NCT03398148
- 45.9% vs 25% NCT03398148
- 53.4% vs 20% NCT03398148
- 37.9% vs 25% NCT03398148
- 42.6% vs 20% NCT03398148
- 32.8% vs 25% NCT03398148
- SHR-1139
- —Not reported
Endoscopic improvement (induction)
- risankizumab
- 36.5% vs 12.1%+24.4 vs placeboNCT03398148
- SHR-1139
- —Not reported
Corticosteroid-free remission (maintenance)
- risankizumab
- —Trial running · NCT03398135
- SHR-1139
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SHR-1139: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. risankizumab: 4 of 4 rows · SHR-1139: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | risankizumab |
|---|---|
| Dropout rate | 4.9%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 10.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.8%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Discontinued due to AEs | 3.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 0%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 3.3%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Serious AEs | 6.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results2.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.5%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.9%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.4%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.5%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 5.6%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.6%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 7.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.7%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Most frequent reported AEs | 1200 mg IV colitis ulcerative 4.9% (placebo 8.5%) headache 4.9% (placebo 5.1%) nasopharyngitis 4.9% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 12 more results1200 mg IV covid-19 4.6% (placebo 0%) anaemia 3.2% (placebo 3.4%) headache 2.9% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.9% (placebo 0%) headache 2.9% (placebo 5.1%) anaemia 1.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.7% (placebo 0%) anaemia 2.9% (placebo 3.4%) colitis ulcerative 1.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC nasopharyngitis 8.5% (placebo 6.8%) headache 7% (placebo 5.1%) colitis ulcerative 4.2% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC anaemia 8.5% (placebo 3.4%) covid-19 8.5% (placebo 0%) headache 8.5% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC headache 2.8% (placebo 5.1%) anaemia 1.4% (placebo 3.4%) nasopharyngitis 1.4% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC covid-19 5.6% (placebo 0%) colitis ulcerative 4.2% (placebo 8.5%) anaemia 2.8% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 8.6% (placebo 6.8%) headache 6.9% (placebo 5.1%) anaemia 1.7% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 7% (placebo 6.8%) headache 6.5% (placebo 5.1%) anaemia 3.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 10.8% (placebo 6.8%) anaemia 2.7% (placebo 3.4%) colitis ulcerative 2.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV dry skin 5.6% (placebo 0%) headache 5.6% (placebo 5.1%) nasopharyngitis 5.6% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 600 mg IV nasopharyngitis 8.1% (placebo 6.8%) bronchitis 6.5% (placebo 0%) dry skin 3.2% (placebo 0%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
risankizumab
show 4 more results
show 3 more results
show 9 more results
show 4 more results
show 3 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: risankizumab's landscape · SHR-1139's landscape